The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific types of stents is unclear. This study aimed to evaluate the clinical non-inferiority at 3 months versus 12 months of dual anti-platelet therapy in patients undergoing coronary angioplasty with zotarolimus-eluting stents. The study randomized 1:1 to 3 months<a href="https://solaci.org/en/2015/06/24/optimize-3-months-versus-12-months-of-dual-anti-aggregation-with-zotarolimus-eluting-stents/" title="Read more" >...</a>

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences clinical outcomes after angioplasty and if the time of double anti-aggregation should be different with the degradable polymer. This work, with non-inferiority design, aimed to compare the sirolimus-eluting biodegradable polymer stent (Tivoli) versus the permanent polymer sirolimus-eluting stent<a href="https://solaci.org/en/2015/06/24/i-love-it2-drug-eluting-stents-with-a-permanent-polymer-versus-biodegradable-in-the-same-cobalt-chromium-platform/" title="Read more" >...</a>

Dangas , George D. (USA)2014-04-25

This multicenter work from Japanrandomized 3200 patients to receive biodegradable polymer biolimus eluting stent(Nobori) or everolimus-eluting stent with permanent polymer (Xience / Promus). The primary end point for efficacy was any revascularizationlesion. A two year follow up the Nobori stent was non-inferior to death or myocardial infarction (7.83% versus 7.69%) and TLR (6.23% versus 5.95%).&nbsp;<a href="https://solaci.org/en/2015/06/24/next-trial-biodegradable-polymer-stent-nobori-was-similar-to-the-permanent-polymer-stents-xience-promus-at-2-years/" title="Read more" >...</a>

The use of drug-eluting stents versus bare metal stents is controversial in some clinical situations in patients at high risk of bleeding.This study randomized 1606 patients considered at low risk of restenosis but with high risk of bleeding receiving Zotarolimus eluting stent (Endeavor) or conventional stent.The clinical characteristics were similar between the two groups with<a href="https://solaci.org/en/2015/06/24/zeus-trial-patients-with-increased-risk-of-bleeding-may-benefit-from-eluting-stents-zotarolimus/" title="Read more" >...</a>

SORT OUT V randomized trial (Odense University Hospital, Denmark) compared Nobori stent, a drug-eluting stent with biodegradable polymer eluting biolimus, versus CYPHER a drug-eluting stent with permanent polymer in the real world. Danish researchers used a non-inferiority design, by means of a primary objective of the study, the combined rate of major cardiac events (cardiac<a href="https://solaci.org/en/2015/06/24/sort-out-v-comparison-of-drug-eluting-stents-one-with-degradable-polymer-releasing-biolimus-and-the-other-a-permanent-polymer-sirolimus-stent/" title="Read more" >...</a>

The EVOLUTION study, (Dr. Junbo Ge, Shanghai Institute, China), compared two sirolimus-eluting stents, one with permanent polymer (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) and another with degradable polymer (Excel, JW Medical System Ltd, Weihai, China). A randomized (2:1) was used, open and non-inferiority, including 1923 patients in 30 centers in China (December 2008<a href="https://solaci.org/en/2015/06/24/evolution-comparative-study-of-non-inferiority-of-two-sirolimus-eluting-stents-one-with-permanent-polymer-and-the-other-with-degradable-polymer/" title="Read more" >...</a>

Summary: Randomized, open, pragmatic essay PROTECT (patient related outcomes of Endeavor versus Cypher stenting trial) compared two drug-eluting stents with different behaviors, (Cypher &reg; and Endeavor &reg;), in the reendothelialization degree and antiproliferative potency. Cypher has a permanent sirolimus-eluting polymer which generates a potent antiproliferative effect and a suboptimal healing (or reendothelialization). Furthermore, Endeavor has<a href="https://solaci.org/en/2015/06/24/protect-a-comparison-of-thrombosis-incidence-between-the-drug-eluting-stents-sirolimus-and-zotarolimus/" title="Read more" >...</a>

Background: Octogenarian patients represent an increasingly growing population. In addition, this age group has a higher proportion of co-morbidities with more extensive and complex coronary disease. However, they have often been excluded from major studies, whose average age is usually 60 years. Despite having a more complex coronary anatomy, the role of pharmacological stent (DES)<a href="https://solaci.org/en/2015/06/24/xima-randomized-prospective-study-comparing-everolimus-eluting-stents-versus-conventional-stent-implantation-in-octogenarians/" title="Read more" >...</a>

Summary: Second-generation drug-eluting stents have shown better results than their predecessors. In this study we compare two second-generation drug stents in patients with unprotected left coronary trunk injuries. Methods and results: 650 patients with unprotected trunk injury were randomized to either XIENCE V (everolimus eluting) or RESOLUTE (zotarolimus eluting) stents. The primary endpoint was the<a href="https://solaci.org/en/2015/06/24/isar-left-main-2-everolimus-eluting-stents-versus-zotarolimus-eluting-stents-in-the-treatment-of-the-unprotected-left-coronary-trunk/" title="Read more" >...</a>